BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 12, 2025
Home » Authors » Shannon Ellis

Articles by Shannon Ellis

Zai nabs China rights to T790-mutation NSCLC drug in Hanmi agreement

Nov. 25, 2015
By Shannon Ellis
SHANGHAI – Zai Labs Ltd., of Shanghai, signed a China rights deal, including Hong Kong and Macau, for a coveted late-stage targeted non-small-cell lung cancer (NSCLC) therapy, HM61713, from Hanmi Pharmaceuticals Co. Ltd., of Seoul, South Korea.
Read More

China-U.S. hybrid Just looks to disrupt sector with affordable biologics

Nov. 25, 2015
By Shannon Ellis
SHANGHAI – Newly formed Just Biotherapeutics Inc., a vertically integrated biotech start-up with a focus on oncology and anti-infectives, has come to life in two places at once, setting up in both Seattle and Hangzhou. In doing so, it is putting an entirely new spin on the usual way of doing business between East and West.
Read More

China-U.S. hybrid Just looks to disrupt sector with affordable biologics

Nov. 24, 2015
By Shannon Ellis

SHANGHAI – Newly formed Just Biotherapeutics Inc., a vertically integrated biotech start-up with a focus on oncology and anti-infectives, has come to life in two places at once, setting up in both Seattle and Hangzhou. In doing so, it is putting an entirely new spin on the usual way of doing business between East and West.


Read More

Wuxi, Lilly unite on CV-targeting small molecule for China

Nov. 18, 2015
By Shannon Ellis
SHANGHAI – For the second time this year, Eli Lilly and Co. entered a strategic collaboration agreement with a local Chinese company to co-develop a novel candidate for the China market, this time with Shanghai-based Wuxi Pharmatech (Cayman) Inc., the well-respected, multifunctional contract research organization (CRO) and contract manufacturer.
Read More

Wuxi, Lilly unite on CV-targeting small molecule for China

Nov. 16, 2015
By Shannon Ellis
SHANGHAI – For the second time this year, Eli Lilly and Co. entered a strategic collaboration agreement with a local Chinese company to co-develop a novel candidate for the China market, this time with Shanghai-based Wuxi Pharmatech (Cayman) Inc., the well-respected, multifunctional contract research organization (CRO) and contract manufacturer.
Read More

Acea's $30M series A to boost pipeline, drug discovery tool business

Nov. 11, 2015
By Shannon Ellis
SHANGHAI – Acea Biosciences Inc., a company that got its start selling instruments used for drug discovery and along the way developed its own pipeline of novel drug compounds, has just closed its first venture round, receiving $30 million from Lilly Asia Ventures and Qiming Venture Partners. Acea is headquartered in San Diego with an instrument plant and additional operations in Hangzhou, Zhejiang.
Read More

China's drug innovation – Is it at a tipping point?

Nov. 11, 2015
By Shannon Ellis
SHANGHAI – Chinese innovation has long been a fraught topic: Does China have it? If so, what is it? When will it be globally relevant? And, if you want to really get people going just ask if China can innovate at all. Some are optimistic that China is on the right path to become a true global innovation participant. McKinsey & Co. decided it was time to tackle that hot topic in its own fashion with a survey of industry leaders who have one foot in China and the other abroad.
Read More

Acea's $30M series A to boost pipeline, drug discovery tool business

Nov. 11, 2015
By Shannon Ellis
SHANGHAI – Acea Biosciences Inc., a company that got its start selling instruments used for drug discovery and along the way developed its own pipeline of novel drug compounds, has just closed its first venture round, receiving $30 million from Lilly Asia Ventures and Qiming Venture Partners. Acea is headquartered in San Diego with an instrument plant and additional operations in Hangzhou, Zhejiang.
Read More

China’s drug innovation – Is it at a tipping point?

Nov. 10, 2015
By Shannon Ellis
SHANGHAI – Chinese innovation has long been a fraught topic: Does China have it? If so, what is it? When will it be globally relevant? And, if you want to really get people going just ask if China can innovate at all. Some are optimistic that China is on the right path to become a true global innovation participant. McKinsey & Co. decided it was time to tackle this hot topic in its own fashion with a survey of industry leaders who have one foot in China and the other abroad.
Read More

Vaccine developer Cansino pads coffers with $30M VC round

Nov. 4, 2015
By Shannon Ellis
SHANGHAI – Tianjin Cansino Inc., the company behind China's phase II Ebola vaccine, has received a $30 million investment from well-respected health care venture firms Qiming Venture Partners and Lilly Asia Ventures.
Read More
Previous 1 2 … 24 25 26 27 28 29 30 31 32 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 6, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing